Cmbio®, a global leader in multi-omics science and digital biology, has announced the acquisition of Eagle Genomics’ innovative enterprise cloud platform, e[datascientist]™, through an Asset Sale Agreement with CBW Recovery LLP and Eagle Genomics Limited (In Administration).
This strategic move enhances Cmbio®’s capabilities in bioinformatics, artificial intelligence (AI), and machine learning (ML), bolstering its position as a leader in the field of digital biology.
Unlocking the potential of multi-omics and digital biology
Eagle Genomics, founded in 2008 and based in Cambridge, UK, gained recognition for its sophisticated cloud software that facilitates the curation, integration, and analysis of complex scientific data.
The acquisition includes all intellectual property related to Eagle Genomics’ platform, enabling Cmbio® to provide researchers and industries with an advanced toolbox for multi-omics research, from microbiome studies to genomics and beyond.
“This acquisition reinforces our commitment to delivering multi-omics science at scale, meeting the future demands of digital biology,” said Anders Grøn, CEO of Cmbio®. Manoj Dadlani, Chairman of Cmbio®, highlighted that the addition of Eagle Genomics’ platform complements Cmbio®’s technology suite, ensuring its position as the preferred global partner for multi-omics services.
Revolutionizing the microbiome analysis market
Cmbio®’s expanded technology portfolio is expected to set new standards in the global microbiome analysis market. With more than 1,000 studies supported across human, animal, and planetary health, the integration of Eagle Genomics’ capabilities allows Cmbio® to offer unprecedented solutions for analyzing and deriving insights from the microbiome and other omics datasets.
The global microbiome analysis market: opportunities and growth
The microbiome analysis market, valued at $1.9 billion in 2024, is projected to exceed $5 billion by 2030, driven by technological advancements, rising investment in microbiome research, and increasing awareness of the microbiome’s impact on health and disease. Cmbio®’s acquisition positions the company as a key player in shaping this rapidly evolving field.
Key market trends
- Integration of multi-omics: increasing demand for platforms that integrate microbiome data with genomics, proteomics, and metabolomics is driving innovation. Cmbio®’s acquisition of Eagle Genomics’ platform aligns perfectly with this trend.
- AI-driven insights: the application of AI and ML to large datasets is becoming essential for deriving actionable insights, creating opportunities for companies like Cmbio® to lead the charge.
- Collaborative research: partnerships between industry and academia are accelerating the development of therapeutics and diagnostics, emphasizing the need for scalable, robust tools like those offered by Cmbio®.
- Personalized medicine: growing interest in using microbiome data for precision medicine is boosting demand for advanced bioinformatics and digital solutions.
Future outlook
With this acquisition, Cmbio® strengthens its role in shaping the future of microbiome analysis and multi-omics science. The integration of Eagle Genomics’ technology into Cmbio®’s existing portfolio will enhance its ability to address the needs of a growing market, empowering researchers and industries worldwide.
As Cmbio® continues to invest in advanced technologies and expand its service offerings, it is poised to remain at the forefront of the microbiome revolution. This acquisition underscores the company’s dedication to advancing the understanding of the microbiome’s impact on human, animal, and planetary health, ultimately driving innovation and transformation in life sciences.
